verified SJR 0,516 · Q3 • database Scopus / SJR & Web of Science indexed

United Kingdom · Taylor and Francis Ltd.

workspace_premium Q3 — Genetics lock Subscription

Pharmacogenomics

Pharmacogenomics is a journal indexed in SJR in Genetics and Pharmacology with an H index of 103. It has an SJR impact factor of 0,516 and it has a best quartile of Q3. It is published in English. It has an SJR impact factor of 0,516.

Pharmacogenomics focuses its scope in these topics and keywords: role, pharmacogenomics, variation, ga, pharmacogenetics, memory, hlab, therapy, ethnic, fentanylgenetic, ...

ISSN: 1462-2416

Publisher: Taylor and Francis Ltd.

Category: Genetics

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

0,516 Q3

H-index 103

Acceptance rate pie_chart

25% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Subscription

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

0,516

H-index

103

Docs (year)

Docs 3y

295

Total refs

2546

Cites 3y

533

Citable 3y

278

Cites/Doc 2y

1.66

Ref/Doc

43.9

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Company Profile: PGXIS Ltd

Who'll be first? Genomic biomarkers impact on drug discovery and clinical practice

DxS Ltd

Drug-induced liver injury: past, present and future

Drug pathways: moving beyond single gene pharmacogenetics

Digene Corporation

Differential Gene Expression 2002'

Developmental and pediatric pharmacogenomics

deCODE genetics, Inc.

CYP2A6polymorphisms and risk for tobacco-related cancers

Court upholds infringement of research tool patents, but discounts damages

Conference Scene: Four decades of modern pharmacogenomics: from promise to clinical utility

SHOW MORE ARTICLES

Comparative and functional analysis of cardiovascular-related genes

A reality check for molecular diagnostics in clinical practice

Chemopreventive drug treatment in subjects with genetic predisposition to cancer: prescriber liability and healthcare disparities

Chemogenomics: tools for protein families' and 'Chemical genomics: chemical and biological integration'

Chemical genomics as an emerging paradigm for postgenomic drug discovery

Candidate gene case-control studies

Bulletin Board

Bioscience 2004

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations

Applications of polymorphisms and pharmacogenomics in obstetrics and gynecology

Anadys Pharmaceuticals, Inc.

An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics

FAQs

Pharmacogenomics has an SJR of 0,516 (best quartile Q3) in the CountryOfPapers database.

Immediate OA APC is not available (NPD).

The acceptance rate recorded for Pharmacogenomics is 25%.

Pharmacogenomics

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Pharmacogenomics?

What is the APC / publication cost?

What is the acceptance rate?